Capstone Investment Advisors
VKTX icon

Capstone Investment Advisors’s Viking Therapeutics VKTX Stock Holding History

Capstone Investment Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,060
Closed -$392K – 1925
2026
Q1 		$392K Buy
+12,060
New +$388K ﹤0.01% 1257
2024
Q2 		– Sell
-41,154
Closed -$3.37M – 2506
2024
Q1 		$3.37M Buy
+41,154
New +$1.83M 0.01% 579
2020
Q1 		– Sell
-38,080
Closed -$305K – 1393
2019
Q4 		$305K Sell
38,080
-2,100
-5% -$15.3K ﹤0.01% 1212
2019
Q3 		$276K Sell
40,180
-39,820
-50% -$296K ﹤0.01% 1188
2019
Q2 		$664K Buy
+80,000
New +$684K ﹤0.01% 1060

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Capstone Investment Advisors's VKTX Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 12,060 shares — an estimated $392K sold.

Capstone Investment Advisors first reported a position in VKTX in Q2 2019 and held it in 5 quarters. The position peaked at $3.37M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,060 Viking Therapeutics shares in Q2 2026, an estimated $392K.
  • Capstone Investment Advisors first reported a position in Viking Therapeutics in Q2 2019 and held it in 5 quarters.
  • Capstone Investment Advisors's Viking Therapeutics position peaked at $3.37M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.